Twenty‐four‐week interim analysis from a phase 3 open‐label...

  • Main
  • 2019 / 07
  • Twenty‐four‐week interim analysis from a phase 3 open‐label...

Twenty‐four‐week interim analysis from a phase 3 open‐label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa

Morita, Akimichi, Takahashi, Hidetoshi, Ozawa, Kentaro, Imafuku, Shinichi, Nakama, Takekuni, Takahashi, Kenzo, Matsuyama, Takashi, Okubo, Yukari, Kitamura, Susumu, Matsuda, Naoto, Zhao, Yiwei, Yokoyam
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
The Journal of Dermatology
DOI:
10.1111/1346-8138.14997
Date:
July, 2019
File:
PDF, 387 KB
2019
Conversion to is in progress
Conversion to is failed